*Review* **Inhibitors of DNA Glycosylases as Prospective Drugs**

#### **Grigory V. Mechetin <sup>1</sup> , Anton V. Endutkin <sup>1</sup> , Evgeniia A. Diatlova <sup>1</sup> and Dmitry O. Zharkov 1,2,\***


Received: 29 March 2020; Accepted: 27 April 2020; Published: 28 April 2020

**Abstract:** DNA glycosylases are enzymes that initiate the base excision repair pathway, a major biochemical process that protects the genomes of all living organisms from intrinsically and environmentally inflicted damage. Recently, base excision repair inhibition proved to be a viable strategy for the therapy of tumors that have lost alternative repair pathways, such as BRCA-deficient cancers sensitive to poly(ADP-ribose)polymerase inhibition. However, drugs targeting DNA glycosylases are still in development and so far have not advanced to clinical trials. In this review, we cover the attempts to validate DNA glycosylases as suitable targets for inhibition in the pharmacological treatment of cancer, neurodegenerative diseases, chronic inflammation, bacterial and viral infections. We discuss the glycosylase inhibitors described so far and survey the advances in the assays for DNA glycosylase reactions that may be used to screen pharmacological libraries for new active compounds.

**Keywords:** DNA repair; DNA glycosylases; drug targets
